The Glucagon-Like Peptide 1 Global Market Report 2023, provides comprehensive information on the glucagon-like peptide 1 market across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa for the 27 major global industries. The report covers a ten year historic period – 2010-2021, and a ten year forecast period – 2023-2032.

Learn More On The Glucagon-Like Peptide 1 Market’s Growth:
https://www.thebusinessresearchcompany.com/report/glucagon-like-peptide-1-global-market-report

The global glucagon-like peptide 1 market size is expected to grow from $18.11 billion in 2022 to $19.51 billion in 2023 at a compound annual growth rate (CAGR) of 7.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global glucagon-like peptide 1 market size is expected to reach $25.89 billion in 2027 at a CAGR of 7.3%.

Get A Free Sample Of The Report (Includes Graphs And Tables):
https://www.thebusinessresearchcompany.com/sample_request?id=10830&type=smp

Technological innovations are a key trend gaining popularity in the global glucagon-like peptide 1 market. Major companies operating in the glucagon-like peptide 1 market are launching new and innovative technologies to sustain their position in the market. For instance, Novo Nordisk A/S, a Denmark-based pharmaceutical company, launched Wegovy, the first and only once-weekly glucagon-like peptide 1 therapy for weight management. Wegovy successfully completed the STEP Phase 3a clinical trial program and demonstrated a safe and well-tolerated profile across the program. This product is used by people who struggle with obesity to achieve and maintain weight loss.

The glucagon-like peptide 1 market is segmented:

1) By Product: Trulicity, Ozempic, Victoza, Rybelsus, Other Types
2) By Route of Administration: Oral, Parenteral, Other Rout
3) By End-Users: Hospitals, Specialty Clinics, Other End Users

North America was the largest region in the glucagon-like peptide 1 market in 2022.

The table of contents in TBRC’s glucagon-like peptide 1 market report includes:

Executive Summary
Market Characteristics
Market Trends And Strategies
Impact Of COVID-19
Market Size And Growth
Segmentation
Regional And Country Analysis
.

.

.

Competitive Landscape And Company Profiles
Key Mergers And Acquisitions
Future Outlook and Potential Analysis
Learn About Us:
The Business Research Company is a market intelligence firm that pioneers in market, company, and consumer research. TBRC’s specialist consultants are located globally and are experts in a wide range of industries that include healthcare, manufacturing, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries. Through the report businesses can gain a thorough understanding of the market’s size, growth rate, major drivers and leading players.

ontact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model